Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN-B1A: results from a phase 3, activecontrolled study (TRANSFORMS)

Aún no traducido Aún no traducido
Categoría Estudio primario
RevistaAbstract meeting of the 64th American Academy of Neurology Annual Meeting
Año 2012
Este artículo no tiene resumen
Epistemonikos ID: 4bb14ffb42d5c900bb325eb9fa1a82591a939693
First added on: Oct 30, 2021